BioPharma Credit (LSE:BPCR) Other Stockholders Equity: $530.0 Mil (As of Dec. 2025)


LSE:BPCR BioPharma Credit PLC LSE:BPCR
52 GF Score
Price $0.96
GF Value $0.96
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Other Stockholders Equity?

BioPharma Credit LSE:BPCR -0.21% 52 Other Stockholders Equity is $530.0 Mil as of Dec. 2025. GuruFocus rates LSE:BPCR with a GF Score™ of 52/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review.

BioPharma Credit's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $530.0 Mil.

BioPharma Credit's quarterly Other Stockholders Equity declined from Dec. 2024 ($560.8 Mil) to Jun. 2025 ($529.4 Mil) but then increased from Jun. 2025 ($529.4 Mil) to Dec. 2025 ($530.0 Mil).

BioPharma Credit's annual Other Stockholders Equity declined from Dec. 2023 ($720.0 Mil) to Dec. 2024 ($560.8 Mil) and declined from Dec. 2024 ($560.8 Mil) to Dec. 2025 ($530.0 Mil).

BioPharma Credit Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit Other Stockholders Equity Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 742.85 716.59 720.00 560.81 530.00

BioPharma Credit Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 720.00 607.21 560.81 529.45 530.00
LSE:BPCR
52GF Score
BioPharma Credit PLC LSE:BPCR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $530.0 Mil mean?
BioPharma Credit (LSE:BPCR) has a Other Stockholders Equity of $530.0 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BioPharma Credit and its competitors.
Is BioPharma Credit's Other Stockholders Equity too high?
BioPharma Credit's current Other Stockholders Equity is $530.0 Mil. Overall, BioPharma Credit has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Other Stockholders Equity compare to BLK and BX?
BioPharma Credit's Other Stockholders Equity of $530.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for an Asset Management company?
A good Other Stockholders Equity depends on the Asset Management industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current Other Stockholders Equity is $530.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading 0.2% below its estimated fair value. The current Other Stockholders Equity is $530.0 Mil. BioPharma Credit's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Other Stockholders Equity is $530.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued. The current stock price of $0.96 is trading 0.2% below its estimated GF Value™ of $0.96. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • Other Stockholders Equity: $530.0 Mil
  • GF Value™: $0.96 vs. price of $0.96 (0.2% below fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
52GF Score

Get the complete analysis for LSE:BPCR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.96
GF Value